ISSN 1662-4009 (online)

ey0017.8-4 | Important for Clinical Practice | ESPEYB17

8.4. Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy

A Osswald , M Quinkler , G Di Dalmazi , T Deutschbein , G Rubinstein , K Ritzel , S Zopp , J Bertherat , F Beuschlein , M Reincke

To read the full abstract: J Clin Endocrinol Metab. 2019; 104(7): 2985–2993. PMID: 30844071.Endogenous Cushing syndrome (CS) is a severe condition characterized by excessive glucocorticoid production (1). In 20% of cases, cortisol is secreted autonomously by the adrenal cortex (2). Adrenal CS is mostly caused by unilateral cortisol-producing adrenal ad...

ey0016.8-10 | Clinical Trials - New Treatments | ESPEYB16

8.10. Treatment of Primary Aldosteronism with mTORC1 Inhibitors

B Trinh , M Hepprich , MJ Betz , T Burkard , C Cavelti-Weder , E Seelig , F Meienberg , DV Kratschmar , F Beuschlein , M Reincke , A Odermatt , MN Hall , MY Donath , MM Swierczynska

To read the full abstract: J Clin Endocrinol Metab. 2019; pii: jc.2019–00563.Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, affecting ~6% of the adult general hypertensive population. Patients with PA are at increased risk of cerebrovascular and cardiovascular morbidity, renal abnormalities and metabolic syndrome. The activity of mTORC1 ...

ey0021.8-3 | Important for Clinical Practice | ESPEYB21

8.3. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency

F Beuschlein , T Else , I Bancos , S Hahner , O Hamidi , L van Hulsteijn , ES Husebye , N Karavitaki , A Prete , A Vaidya , C Yedinak , OM Dekkers

Brief Summary: This article presents the joint European Society of Endocrinology and Endocrine Society clinical guideline on the diagnosis and treatment of Glucocorticoid (GC)-induced adrenal insufficiencyComment: The prevalence of oral glucocorticoid (GC) use is ~1% in adults (1). The risk for glucocorticoid-induced adrenal insufficiency is evident. These guidelines provide both endocrinologists and general practitioners with guidance to manage such pat...

ey0018.8-7 | Important for Clinical Practice | ESPEYB18

8.7. Targeted metabolomics as a tool in discriminating endocrine from primary hypertension

Z Erlic , P Reel , S Reel , L Amar , A Pecori , CK Larsen , M Tetti , C Pamporaki , C Prehn , J Adamski , A Prejbisz , F Ceccato , C Scaroni , M Kroiss , MC Dennedy , J Deinum , K Langton , P Mulatero , M Reincke , L Lenzini , AP Gimenez-Roqueplo , G Assie , A Blanchard , MC Zennaro , E Jefferson , F Beuschlein

J Clin Endocrinol Metab. 2021 Mar 25;106(4):1111–1128.https://pubmed.ncbi.nlm.nih.gov/33382876/In this multicentre patient cohort study, the authors investigated the use of targeted metabolomics to discriminate primary hypertension (PHT) from endocrine forms of hypertension (EHT). They identified 16 metabolites that help to discriminate between PHT and EHT.Arteri...

ey0020.6-11 | New Genes | ESPEYB20

6.11. Identification of risk loci for primary aldosteronism in genome-wide association studies

E Le Floch , T Cosentino , CK Larsen , F Beuschlein , M Reincke , L Amar , GP Rossi , K De Sousa , S Baron , S Chantalat , B Saintpierre , L Lenzini , A Frouin , I Giscos-Douriez , M Ferey , AB Abdellatif , T Meatchi , JP Empana , X Jouven , C Gieger , M Waldenberger , A Peters , D Cusi , E Salvi , P Meneton , M Touvier , M Deschasaux , N Druesne-Pecollo , S Boulkroun , FL Fernandes-Rosa , JF Deleuze , X Jeunemaitre , MC Zennaro

Brief summary: This genome-wide association study (GWAS) reports the first genetic loci for risk of primary aldosteronism. New candidate genes and their potential mechanisms for the development of aldosterone excess are described.Primary aldosteronism (PA) is the most frequent form of secondary hypertension (5% of patients with hypertension in primary care and 10–20% of patients with hypertension referred to specialist care). PA is associated with c...

ey0021.8-15 | New Hope | ESPEYB21

8.15. Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses

A Fischer , S Kloos , U Maccio , J Friemel , H Remde , M Fassnacht , C Pamporaki , G Eisenhofer , HJLM Timmers , M Robledo , SMJ Fliedner , K Wang , J Maurer , A Reul , K Zitzmann , N Bechmann , G Žygienė , S Richter , C Hantel , D Vetter , K Lehmann , H Mohr , NS Pellegata , M Ullrich , J Pietzsch , CG Ziegler , SR Bornstein , M Kroiss , M Reincke , K Pacak , AB Grossman , F Beuschlein , S Nolting

Brief Summary: This study explored the relationship between Somatostatin Receptor 2 (SSTR2) immunoreactivity and succinate dehydrogenase complex iron sulfur subunit B (SDHB) immunoreactivity, mutational status, and clinical behavior of paragangliomas (PPGLs), and evaluated SSTR-based therapies in metastatic PPGLs. The findings highlight SSTR2 expression as a novel biomarker for metastatic behavior in PCC, PGL and SDHB/ SDHx mutations. They also suggest that SSTR-based therapie...